Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.

Authors

null

Jose Pablo Leone

University of Pittsburgh Cancer Institute, Pittsburgh, PA

Jose Pablo Leone , Diana E. Cunningham , Adrian Lee , Rohit Bhargava , Ronald L. Hamilton , Erik Wiener , Hideho Okada , Adam Brufsky

Organizations

University of Pittsburgh Cancer Institute, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Research Funding

No funding sources reported

Background: BC is the second most frequent cause of BM after lung cancer, with metastases occurring in 10% - 16% of all patients. BM in patients with BC is a catastrophic event that results in poor prognosis. Identification of prognostic factors associated with breast cancer brain metastases (BCBM) could help to identify patients at risk. The aim of this study was to assess clinical characteristics, prognostic factors and survival of patients with BCBM who had craniotomy and resection in a series of patients treated with modern multimodality therapy. Methods: We analyzed 42 patients with BCBM who underwent resection. Patients were diagnosed with BC between April 1994 and May 2010. Cox proportional hazards regression was selected to describe factors associated with time to BM, survival from the date of first recurrence, and overall survival (OS). Results: Median age was 51 years (range 24-74). Median follow-up was 4.2 years (range 0.6-18.5). The mean time to BM from primary diagnosis was 49 months (range 0-206.22). Patients had a median of 2 BM with a median size of 3.25 cm. The proportion of the biological subtypes of BC was ER+/HER2- 25%, ER+/HER2+ 15%, ER-/HER2+ 30% and ER-/HER2- 30%. Brain radiotherapy was given to 28 patients, of which 10 had stereotactic radiosurgery, 7 whole brain radiation, and 11 both. Median OS from the date of primary diagnosis was 5.74 years. Median survival after diagnosis of BM was 1.33 years. In multivariate Cox regression analyses, stage was the only factor associated with shorter time to the development of BM (P=0.059), whereas age was the only factor associated with survival from the date of recurrence (P=0.027) and with OS (P=0.037). Controlling for age and stage, neither the biological subtype of cancer, the radiation modality nor the site of first recurrence showed any impact on survival. Conclusions: Stage at primary diagnosis correlated with shorter time to the development of BM, while age at diagnosis was associated with shorter survival in BCBM. None of the other clinical factors had influence on survival.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 Breast Cancer Symposium

Session Type

Poster Discussion Session

Session Title

General Session VIII: Poster Discussion B

Track

Risk Assessment, Prevention, Detection, and Screening,Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy

Sub Track

Advanced Disease

Citation

J Clin Oncol 31, 2013 (suppl 26; abstr 143)

DOI

10.1200/jco.2013.31.26_suppl.143

Abstract #

143

Poster Bd #

B1

Abstract Disclosures

Similar Abstracts

First Author: Jose Pablo Leone

Abstract

2023 ASCO Annual Meeting

Trends in breast cancer death by stage at diagnoses in 2000-2018.

First Author: Adriana Matutino Kahn

First Author: Erin Aiello Bowles